14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Predictions

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022
Currently predicting for Fri, 26 Apr 2024

CATB Predictions History

3 years ago
JS predicted that CATB for 2021-02-01 is going $3.85 (5.77%)

3 years ago
Natacha Gaymer-Jones predicted that CATB for 2021-02-01 is going

Rank:

3 years ago
JS predicted that CATB for 2020-10-27 is going $5.46 (250.00%)

3 years ago
DeMichael Franklin predicted that CATB for 2020-10-27 is going $1.50 (-3.85%)

Rank:

4 years ago
JS predicted that CATB for 2020-01-17 is going

4 years ago
2poJeff predicted that CATB for 2020-01-17 is going $6.88 (-1.71%)

4 years ago
Yep.Nope.94361 predicted that CATB for 2020-01-17 is going $6.79 (-3.00%)

Rank:

5 years ago
Curtis Allen predicted that CATB for 2019-01-25 is going $6.34 (2.59%)

Rank:

6 years ago
Cathy.Akhtar.11824 predicted that CATB for 2017-09-19 is going $1.50 (-6.25%)

Rank:

6 years ago
JS predicted that CATB for 2017-09-15 is going $1.65 (-2.37%)

Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT